Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.67 |
| ▸ | ACHE | P22303 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| O-Xylene SCHEMBL27496500 | 0.87 | TSHR (0.67) | TSHRACHEALDH1A1CA1CA2 | |
| O-Xylene SCHEMBL27492161 | 0.86 | TSHR (0.91) | TSHRACHEALDH1A1CA1CA2 | |
| O-Xylene SCHEMBL22719990 | 0.86 | TSHR (0.91) | TSHRACHEALDH1A1CA1CA2 | |
| O-Xylene SCHEMBL11875587 | 0.86 | — | — | |
| O-Xylene SCHEMBL30184332 | 0.86 | — | — | |
| O-Xylene SCHEMBL8556899 | 0.84 | TSHR (0.62) | TSHRACHEALDH1A1CA1CA2 | |
| O-Xylene SCHEMBL9818029 | 0.83 | TSHR (0.46) | TSHRACHEALDH1A1CA1CA2 | |
| O-Xylene SCHEMBL10999223 | 0.82 | TSHR (0.83) | TSHRACHEALDH1A1CA1CA2 | |
| O-Xylene SCHEMBL28002440 | 0.82 | TSHR (0.83) | TSHRACHEALDH1A1CA1CA2 | |
| O-Xylene SCHEMBL27520441 | 0.82 | TSHR (0.83) | TSHRACHEALDH1A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9827559-B2 | Method for preparing nano metal/metal oxide loaded molecular sieve catalyst | Changzhou University (CN) | 2017-11-28 | — | — | US | claimed |
| US-20160074849-A1 | METHOD FOR PREPARING NANO METAL/METAL OXIDE LOADED MOLECULAR SIEVE CATALYST | Changzhou University | 2016-03-17 | — | — | US | claimed |
| EP-2475663-A2 | PALIPERIDONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF IMPURITIES | Actavis Group Ptc Ehf (IS) | 2012-07-18 | — | — | EP | claimed |
| US-20120164188-A1 | PALIPERIDONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF IMPURITIES | ACTAVIS GROUP PTC EHF (IS) | 2012-06-28 | — | — | US | claimed |
| WO-2011030224-A2 | PALIPERIDONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF IMPURITIES | ACTAVIS GROUP PTC EHF (IS) | 2011-03-17 | — | — | WO | claimed |
| WO-2024019137-A1 | PRODUCTION METHOD OF OLIGONUCLEOTIDE | 住友化学株式会社 | 2024-01-25 | — | — | WO | disclosed |
| CN-107250283-B | Compounds and compositions containing the same | 住友化学株式会社 | 2019-09-10 | — | — | CN | disclosed |
| CN-107193072-B | Elliptical polarization plate | 住友化学株式会社 | 2018-08-28 | — | — | CN | disclosed |
| US-9827559-B2 | Method for preparing nano metal/metal oxide loaded molecular sieve catalyst | Changzhou University (CN) | 2017-11-28 | — | — | US | disclosed |
| CN-107250283-A | compounds and compositions containing the same | 住友化学株式会社 | 2017-10-13 | — | — | CN | disclosed |
| CN-107250322-A | Composition comprising a metal oxide and a metal oxide | 住友化学株式会社 | 2017-10-13 | — | — | CN | disclosed |
| CN-107193072-A | Elliptical polarization plate | 住友化学株式会社 | 2017-09-22 | — | — | CN | disclosed |
| CN-1324359-A | Tricyclic carboxamides | SMITHKLINE BEECHAM PLC (GB) | 2001-11-28 | — | — | CN | disclosed |
| CN-1319081-A | Method for pressureless production of alpha, alpha-dimethylphenyl acetic acid from alpha, alpha-dimethyl benzyl cyanide | AVENTIS PHARMA GMBH (DE) | 2001-10-24 | — | — | CN | disclosed |
| CN-1305492-A | Pyrazinone protease inhibitors | DIMENSIONAL PHARM INC (US) | 2001-07-25 | — | — | CN | disclosed |
| CN-1211248-A | Novel substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) [1,4] diazepan-1-yl)-1-(aryl) butyl) benzamides useful for treatment of allergic diseases | HOECHST MARION ROUSSEL INC (US) | 1999-03-17 | — | — | CN | disclosed |
| EP-0668260-B1 | Process for phosgenation in the presence of acetonitrile | ZENECA LTD (GB) | 1998-08-12 | — | — | EP | disclosed |
| US-5792888-A | Process for phosgenation in the presence of acetonitrile | ZENECA LIMITED (GB) | 1998-08-11 | — | — | US | disclosed |
| WO-1996024558-A1 | METHOD AND APPARATUS FOR THERMAL DECOMPOSITION AND SEPARATION OF COMPONENTS WITHIN AN AQUEOUS STREAM | HPR CORPORATION (US) | 1996-08-15 | — | — | WO | disclosed |
| EP-0668260-A1 | Process for phosgenation in the presence of acetonitrile | ZENECA LIMITED (GB) | 1995-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120164188-A1 | PALIPERIDONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF IMPURITIES | REN, DHPS, AVPR2 | TSHR 3098/4885ACHE 4730/4885ALDH1A1 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.